Franz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology.
Franz Obermayr, PhD
Dr. Franz Obermayr is Co-Founder and serves as CEO of Panoptes. Before that he was Head of Clinical Development at Nabriva, where he led the clinical efforts to show clinical POC in a phase 2b study leading to the successful Biotech-deal with Forest Laboratories.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.